- Home
- CORT
as 05-09-2025 9:49am EST
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 7.1B | IPO Year: | N/A |
| Target Price: | $142.00 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.14 | EPS Growth: | 8.36 |
| 52 Week Low/High: | $25.35 - $117.33 | Next Earning Date: | 05-05-2025 |
| Revenue: | $685,446,000 | Revenue Growth: | 30.93% |
| Revenue Growth (this year): | 36.81% | Revenue Growth (next year): | 32.00% |
Stock Insider Trading Activity of Corcept Therapeutics Incorporated (CORT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lyon Joseph Douglas | CORT | See Remarks | May 1 '25 | Sell | $71.96 | 9,350 | $672,781.12 | 9,009 | |
| Maduck Sean | CORT | See Remarks | May 1 '25 | Sell | $72.37 | 39,410 | $2,842,769.23 | 85,622 | |
| Swisher Daniel N JR | CORT | Director | Apr 10 '25 | Sell | $70.22 | 2,200 | $154,484.00 | 0 | |
| Guyer William | CORT | Chief Development Officer | Apr 1 '25 | Sell | $114.51 | 678 | $77,639.00 | 5,487 | |
| Lyon Joseph Douglas | CORT | See Remarks | Mar 31 '25 | Sell | $104.65 | 200,650 | $20,167,953.55 | 9,009 | |
| Maduck Sean | CORT | See Remarks | Mar 31 '25 | Sell | $104.60 | 100,590 | $10,121,593.92 | 85,622 | |
| BELANOFF JOSEPH K | CORT | Chief Executive Officer | Mar 31 '25 | Sell | $104.72 | 35,452 | $3,365,009.94 | 2,981,985 | |
| Lyon Joseph Douglas | CORT | See Remarks | Mar 24 '25 | Sell | $60.58 | 421 | $25,504.18 | 9,009 | |
| Maduck Sean | CORT | See Remarks | Mar 24 '25 | Sell | $60.58 | 1,697 | $102,804.26 | 85,622 | |
| BELANOFF JOSEPH K | CORT | Chief Executive Officer | Mar 24 '25 | Sell | $60.83 | 1,974 | $120,084.14 | 2,981,985 |
Latest Corcept Therapeutics Incorporated News
CORT Breaking Stock News: Dive into CORT Ticker-Specific Updates for Smart Investing
StockStory
a day ago
1 Small-Cap Stock Worth Your Attention and 2 to Question
TipRanks
2 days ago
Corcept Therapeutics price target lowered to $135 from $150 at Truist
Argus Research
3 days ago
CORT: Lowering target price to $78.00
Thomson Reuters StreetEvents
3 days ago
Q1 2025 Corcept Therapeutics Inc Earnings Call
Simply Wall St.
3 days ago
Corcept Therapeutics (NasdaqCM:CORT) Reports US$21M Q1 Net Income Lowers EPS
Zacks
3 days ago
CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall
MT Newswires
3 days ago
Corcept Therapeutics Insider Sold Shares Worth $2,915,922, According to a Recent SEC Filing
MT Newswires
3 days ago
Corcept Therapeutics Insider Sold Shares Worth $2,842,769, According to a Recent SEC Filing
Compare CORT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CORT Corcept Therapeutics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.